Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
Part of paid clinical trials in Indianapolis, Indiana.
- Sponsor
- Indiana University
- Study ID
- NCT07825454
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
- Breast Cancer
- Joint Pain
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Hydroxychloroquine Sulfate (HCQ) — DRUGDrug: Hydroxychloroquine sulfate Dose: 400 mg orally once daily Duration: 12 weeks
Study Details
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase Inhibitor Associated Musculoskeletal Syndrome (AIMSS) for patients with breast cancer.
Key Dates
- First listed
- Sep 17, 2026
- Start date
- Sep 30, 2026
- Status verified
- Sep 2026
- Primary completion
- Dec 31, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 35 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Hydroxychloroquine sulfateHydroxychloroquine sulfate, 400 mg orally once daily
Primary Outcome Measure
To evaluate the efficacy of hydroxychloroquine [ Time Frame: Day 1 and Week 12 ]
Central Contacts
- Niraj Shah, MS317-278-3420
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | Tarah Ballinger, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Indianapolis, IN
By condition
By specialty
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Anchorage, Alaska
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerPHASE2 · Recruiting · Abramson Cancer Center at Penn Medicine · Washington D.C., District of Columbia
- ATEMPT 2.0: Adjuvant T-DM1 vs THPHASE2 · Recruiting · Dana-Farber Cancer Institute · San Francisco, California